Aarash Bordbar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aarash Bordbar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Bloem
Sinopia Biosciences, San Diego, CA, USA
1 shared publication - Bernhard O. Palsson
Department of Bioengineering, University of California San Diego
1 shared publication - Caesar Tawfeeq
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA
1 shared publication - Colton Joseph Lloyd
University of California San Diego
1 shared publication - Daniel Craig Zielinski
Department of Bioengineering, University of California San Diego , La Jolla, CA 92093
1 shared publication Daniel R. Hyduke
Department of Bioengineering, University of California San Diego, La Jolla, California, United States of America
1 shared publication
Latest Publications
- 15 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (858) , eaec7409
A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.
Maximizing clinical benefits of therapeutics while minimizing adverse effects is a central challenge in drug development. For Parkinson's disease (PD), l-3,4-dihydroxyphenylalanine (l-dopa) is the most effective treatment available, but chronic use is associated with periods of reduced efficacy (motor fluctuations) and the debilitating on-target side effect of l-dopa-induced dyskinesia. To disentangle the molecular mechanisms underlying l-dopa's antiparkinsonian effects versus its dyskinetic effects, we analyzed transcriptomic data from the striata of mice exposed to different l-dopa doses, identifying distinct gene expression signatures associated with l-dopa's effect on parkinsonian motor symptoms and dyskinesia. By comparing these gene expression signatures with a large dataset of in vitro gene expression profiles of drug perturbations, we identified SB-0107, a positive allosteric modulator of protein kinase A type II with previous clinical experience that boosts l-dopa's benefits while reducing dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque model of PD. Deuterated analogs, including SB-0110, were developed that improved both pharmacokinetics and pharmacological effects. This dual effect, established safety profile of the parent compound, and improved properties of the deuterated analog support further development of this compound as an adjunct treatment to l-dopa therapy for PD.
- 15 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (858) , eaec7409
A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.
Maximizing clinical benefits of therapeutics while minimizing adverse effects is a central challenge in drug development. For Parkinson's disease (PD), l-3,4-dihydroxyphenylalanine (l-dopa) is the most effective treatment available, but chronic use is associated with periods of reduced efficacy (motor fluctuations) and the debilitating on-target side effect of l-dopa-induced dyskinesia. To disentangle the molecular mechanisms underlying l-dopa's antiparkinsonian effects versus its dyskinetic effects, we analyzed transcriptomic data from the striata of mice exposed to different l-dopa doses, identifying distinct gene expression signatures associated with l-dopa's effect on parkinsonian motor symptoms and dyskinesia. By comparing these gene expression signatures with a large dataset of in vitro gene expression profiles of drug perturbations, we identified SB-0107, a positive allosteric modulator of protein kinase A type II with previous clinical experience that boosts l-dopa's benefits while reducing dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque model of PD. Deuterated analogs, including SB-0110, were developed that improved both pharmacokinetics and pharmacological effects. This dual effect, established safety profile of the parent compound, and improved properties of the deuterated analog support further development of this compound as an adjunct treatment to l-dopa therapy for PD.
- Open Access
- 18 September 2014
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 10 (9) , e1003837
A Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks
Altered metabolism in cancer cells has been viewed as a passive response required for a malignant transformation. However, this view has changed through the recently described metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH) that produce oncometabolites that competitively inhibit epigenetic regulation. In this study, we demonstrate in silico predictions of oncometabolites that have the potential to dysregulate epigenetic controls in nine types of cancer by incorporating massive scale genetic mutation information (collected from more than 1,700 cancer genomes), expression profiling data, and deploying Recon 2 to reconstruct context-specific genome-scale metabolic models. Our analysis predicted 15 compounds and 24 substructures of potential oncometabolites that could result from the loss-of-function and gain-of-function mutations of metabolic enzymes, respectively. These results suggest a substantial potential for discovering unidentified oncometabolites in various forms of cancers. Cancer and metabolism have been considered to be associated for a long period since Otto Warburg observed that tumor cells consume glucose and convert most of it to lactate, despite the presence of oxygen. However, the role of the Warburg effect in oncogenesis had been under doubt because no solid links between genetic variations in metabolic genes and cancer had been observed until recent days. When with the development of sequencing technologies, researchers found mutations in IDH1, IDH2 (isocitrate dehydrogenase) in medium-grade glioma and acute leukemia. As these mutated metabolic genes initiate unexpected enzymatic reactions, cancer cells show altered concentration of particular metabolites, here called “oncometabolites”. The oncometabolites regulate the epigenetic controls of cell differentiations. In this study, we predict potential oncometabolites that might originate from loss or gain-of-function mutations in nine types of cancer from massive scale cancer mutation data with a systems biology approach.
- 18 September 2014
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 10 (9) , e1003837
Open AccessA Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks
Altered metabolism in cancer cells has been viewed as a passive response required for a malignant transformation. However, this view has changed through the recently described metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH) that produce oncometabolites that competitively inhibit epigenetic regulation. In this study, we demonstrate in silico predictions of oncometabolites that have the potential to dysregulate epigenetic controls in nine types of cancer by incorporating massive scale genetic mutation information (collected from more than 1,700 cancer genomes), expression profiling data, and deploying Recon 2 to reconstruct context-specific genome-scale metabolic models. Our analysis predicted 15 compounds and 24 substructures of potential oncometabolites that could result from the loss-of-function and gain-of-function mutations of metabolic enzymes, respectively. These results suggest a substantial potential for discovering unidentified oncometabolites in various forms of cancers. Cancer and metabolism have been considered to be associated for a long period since Otto Warburg observed that tumor cells consume glucose and convert most of it to lactate, despite the presence of oxygen. However, the role of the Warburg effect in oncogenesis had been under doubt because no solid links between genetic variations in metabolic genes and cancer had been observed until recent days. When with the development of sequencing technologies, researchers found mutations in IDH1, IDH2 (isocitrate dehydrogenase) in medium-grade glioma and acute leukemia. As these mutated metabolic genes initiate unexpected enzymatic reactions, cancer cells show altered concentration of particular metabolites, here called “oncometabolites”. The oncometabolites regulate the epigenetic controls of cell differentiations. In this study, we predict potential oncometabolites that might originate from loss or gain-of-function mutations in nine types of cancer from massive scale cancer mutation data with a systems biology approach.